亚辉龙2025年归母净利润预计同比下降超90% “脑机接口”热度还没蹭上反被火速警示？

Core Viewpoint - The company, YHLO Biotech, is facing a significant decline in profits after experiencing explosive growth during the COVID-19 pandemic, with a projected net profit drop of over 90% for 2025 [1][2][4]. Group 1: Company Performance - YHLO Biotech's main business involves the development, production, and sales of in vitro diagnostic instruments and related reagents, focusing on various core disease areas [2][16]. - The company's revenue peaked in 2022, with a 238% increase, largely driven by the demand for COVID-19 antigen test kits [2][16]. - For 2023 and 2024, the company's revenue is projected to be 20.53 billion and 20.12 billion respectively, showing a year-on-year decline of 48.42% and 2.02% [4][18]. Group 2: Profit Forecast - YHLO Biotech announced on January 31 that it expects a net profit attributable to shareholders of 20 million to 30 million for 2025, a decrease of 270 million to 280 million from the previous year, representing a decline of 90.05% to 93.37% [4][19]. - The company's non-recurring net profit is expected to be between 65 million and 85 million, down 70.42% to 77.38% year-on-year [4][19]. Group 3: Strategic Partnership - On January 6, YHLO Biotech announced a strategic partnership with Shenzhen Brain-Computer Link Technology Co., Ltd. to develop brain-computer interface-related products [1][9]. - The partnership aims to integrate brain-computer interface technology with clinical and market resources to enhance diagnostic capabilities in central nervous system diseases [9][24]. - The company plans to invest no more than 15 million RMB in this partnership, which is still in its early stages and is not expected to significantly impact performance in the short term [12][26]. Group 4: Market Reaction and Regulatory Scrutiny - Following the announcement of the partnership, YHLO Biotech's stock price rose by 6.52%, with trading volume increasing by 299% [9][24]. - The Shanghai Stock Exchange issued an inquiry to YHLO Biotech regarding the clarity and accuracy of its disclosures related to the partnership, highlighting inconsistencies in the description of the technology involved [10][28]. - The company has been criticized for potentially engaging in "concept hype" by using vague language that could mislead investors about the nature of the technology [27][28].